JP2016525543A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016525543A5 JP2016525543A5 JP2016529739A JP2016529739A JP2016525543A5 JP 2016525543 A5 JP2016525543 A5 JP 2016525543A5 JP 2016529739 A JP2016529739 A JP 2016529739A JP 2016529739 A JP2016529739 A JP 2016529739A JP 2016525543 A5 JP2016525543 A5 JP 2016525543A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- disease
- pharmaceutically active
- additional pharmaceutically
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 239000004480 active ingredient Substances 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000030090 Acute Disease Diseases 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- LGEQQWMQCRIYKG-DOFZRALJSA-N anandamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO LGEQQWMQCRIYKG-DOFZRALJSA-N 0.000 claims 2
- LGEQQWMQCRIYKG-UHFFFAOYSA-N arachidonic acid ethanolamide Natural products CCCCCC=CCC=CCC=CCC=CCCCC(=O)NCCO LGEQQWMQCRIYKG-UHFFFAOYSA-N 0.000 claims 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 2
- 206010061428 decreased appetite Diseases 0.000 claims 2
- 206010013663 drug dependence Diseases 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- BOWVQLFMWHZBEF-KTKRTIGZSA-N oleoyl ethanolamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)NCCO BOWVQLFMWHZBEF-KTKRTIGZSA-N 0.000 claims 2
- 229950007031 palmidrol Drugs 0.000 claims 2
- HXYVTAGFYLMHSO-UHFFFAOYSA-N palmitoyl ethanolamide Chemical compound CCCCCCCCCCCCCCCC(=O)NCCO HXYVTAGFYLMHSO-UHFFFAOYSA-N 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 208000011117 substance-related disease Diseases 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- 206010012335 Dependence Diseases 0.000 claims 1
- 208000012661 Dyskinesia Diseases 0.000 claims 1
- 208000014094 Dystonic disease Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 101000918494 Homo sapiens Fatty-acid amide hydrolase 1 Proteins 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- 208000007201 Myocardial reperfusion injury Diseases 0.000 claims 1
- 150000001200 N-acyl ethanolamides Chemical class 0.000 claims 1
- 206010028813 Nausea Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010029350 Neurotoxicity Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010030043 Ocular hypertension Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims 1
- 206010044221 Toxic encephalopathy Diseases 0.000 claims 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000005796 circulatory shock Effects 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- 208000016097 disease of metabolism Diseases 0.000 claims 1
- 208000010118 dystonia Diseases 0.000 claims 1
- 239000002621 endocannabinoid Substances 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 210000002816 gill Anatomy 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- 229960004502 levodopa Drugs 0.000 claims 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000008693 nausea Effects 0.000 claims 1
- 230000003880 negative regulation of appetite Effects 0.000 claims 1
- 230000007135 neurotoxicity Effects 0.000 claims 1
- 231100000228 neurotoxicity Toxicity 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 229940127240 opiate Drugs 0.000 claims 1
- 230000036407 pain Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000003368 psychostimulant agent Substances 0.000 claims 1
- 229940043131 pyroglutamate Drugs 0.000 claims 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 239000000758 substrate Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1313202.2 | 2013-07-24 | ||
| GB1313203.0 | 2013-07-24 | ||
| GB201313204A GB201313204D0 (en) | 2013-07-24 | 2013-07-24 | Urea compound and its use as an enzyme inhibitor |
| GB201313203A GB201313203D0 (en) | 2013-07-24 | 2013-07-24 | Urea compound and its use as an enzyme inhibitor |
| GB201313202A GB201313202D0 (en) | 2013-07-24 | 2013-07-24 | Urea Compound And Its Use As An Enzyme Inhibitor |
| GB1313204.8 | 2013-07-24 | ||
| PCT/PT2014/000049 WO2015012708A1 (en) | 2013-07-24 | 2014-07-24 | Imidazolecarboxamides and their use as faah inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016525543A JP2016525543A (ja) | 2016-08-25 |
| JP2016525543A5 true JP2016525543A5 (enExample) | 2017-08-31 |
| JP6449277B2 JP6449277B2 (ja) | 2019-01-09 |
Family
ID=51358056
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016529739A Expired - Fee Related JP6449277B2 (ja) | 2013-07-24 | 2014-07-24 | イミダゾールカルボキサミドおよびｆａａｈ阻害剤としてのそれらの使用 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US10501447B2 (enExample) |
| EP (1) | EP3024825B1 (enExample) |
| JP (1) | JP6449277B2 (enExample) |
| KR (1) | KR20160034359A (enExample) |
| CN (1) | CN105793247B (enExample) |
| AU (1) | AU2014293731B2 (enExample) |
| CA (1) | CA2918993C (enExample) |
| CY (1) | CY1119482T1 (enExample) |
| DK (1) | DK3024825T3 (enExample) |
| ES (1) | ES2640800T3 (enExample) |
| HR (1) | HRP20171378T1 (enExample) |
| HU (1) | HUE033615T2 (enExample) |
| LT (1) | LT3024825T (enExample) |
| MX (1) | MX362315B (enExample) |
| PL (1) | PL3024825T3 (enExample) |
| PT (1) | PT3024825T (enExample) |
| RS (1) | RS56297B1 (enExample) |
| RU (1) | RU2671404C2 (enExample) |
| SI (1) | SI3024825T1 (enExample) |
| WO (1) | WO2015012708A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12018000077B1 (en) | 2017-07-05 | 2021-07-09 | Frimline Private Ltd | A pharmaceutical composition for neuropathic pain |
| US10702487B2 (en) | 2017-08-19 | 2020-07-07 | Frimline Private Limited | Pharmaceutical composition for prevention of diet induced obesity |
| PH12018000227A1 (en) | 2017-09-05 | 2019-03-11 | Frimline Private Ltd | A pharmaceutical composition for improving or preventing progression of chronic kidney disease |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2458965C3 (de) | 1974-12-13 | 1979-10-11 | Bayer Ag, 5090 Leverkusen | 3-Amino-indazol-N-carbonsäure-Derivate, Verfahren zu ihrer Herstellung sowie sie enthaltende Arzneimittel |
| EP0014810A3 (en) | 1979-01-18 | 1980-11-26 | Fbc Limited | Pesticidal pyrazoles, their production, compositions and uses, as well as intermediates and their preparation |
| JPH01203366A (ja) | 1988-02-10 | 1989-08-16 | Mitsui Petrochem Ind Ltd | Ｎ−置換イミダゾール誘導体 |
| EP0665226A1 (en) | 1992-10-28 | 1995-08-02 | Toyama Chemical Co., Ltd. | Novel 1,2-benzisoxazole derivative or salt thereof, and brain protective agent comprising the same |
| DE102004005172A1 (de) | 2004-02-02 | 2005-08-18 | Aventis Pharma Deutschland Gmbh | Indazolderivate als Inhibitoren der Hormon Sensitiven Lipase |
| ES2639621T3 (es) * | 2004-12-30 | 2017-10-27 | Janssen Pharmaceutica N.V. | Derivados de fenilamida del ácido 4-(bencil)-piperazina-1-carboxílico y compuestos relacionados como moduladores de la amida hidrolasa de ácidos grasos (FAAH) para el tratamiento de la ansiedad, el dolor y otras afecciones |
| FI20075264A0 (fi) | 2007-04-18 | 2007-04-18 | Kuopion Yliopisto | Heterosykliset fenyylikarbamaatit uusina FAAH-inhibiittoreina |
| WO2009126624A1 (en) | 2008-04-11 | 2009-10-15 | Bristol-Myers Squibb Company | Triazolo compounds useful as dgat1 inhibitors |
| CN105399731A (zh) | 2008-12-24 | 2016-03-16 | 比亚尔-珀特拉和Ca股份公司 | 药物化合物 |
| CA2806701A1 (en) | 2010-07-29 | 2012-02-02 | Bial - Portela & Ca, S.A. | Process for the synthesis of substituted urea compounds |
| FR2965262A1 (fr) | 2010-09-24 | 2012-03-30 | Sanofi Aventis | Derives de nicotinamide, leur preparation et leur application en therapeutique |
| ME03018B (me) | 2012-07-24 | 2018-10-20 | Bial Portela & Ca Sa | Jedinjena uree i njhova upotreba као inhibitora enzima |
-
2014
- 2014-07-24 AU AU2014293731A patent/AU2014293731B2/en not_active Ceased
- 2014-07-24 EP EP14752676.8A patent/EP3024825B1/en active Active
- 2014-07-24 JP JP2016529739A patent/JP6449277B2/ja not_active Expired - Fee Related
- 2014-07-24 WO PCT/PT2014/000049 patent/WO2015012708A1/en not_active Ceased
- 2014-07-24 HR HRP20171378TT patent/HRP20171378T1/hr unknown
- 2014-07-24 LT LTEP14752676.8T patent/LT3024825T/lt unknown
- 2014-07-24 CN CN201480041611.9A patent/CN105793247B/zh not_active Expired - Fee Related
- 2014-07-24 SI SI201430380T patent/SI3024825T1/sl unknown
- 2014-07-24 RS RS20170905A patent/RS56297B1/sr unknown
- 2014-07-24 PT PT147526768T patent/PT3024825T/pt unknown
- 2014-07-24 CA CA2918993A patent/CA2918993C/en not_active Expired - Fee Related
- 2014-07-24 US US14/906,822 patent/US10501447B2/en not_active Expired - Fee Related
- 2014-07-24 DK DK14752676.8T patent/DK3024825T3/en active
- 2014-07-24 KR KR1020167004236A patent/KR20160034359A/ko not_active Abandoned
- 2014-07-24 PL PL14752676T patent/PL3024825T3/pl unknown
- 2014-07-24 ES ES14752676.8T patent/ES2640800T3/es active Active
- 2014-07-24 HU HUE14752676A patent/HUE033615T2/hu unknown
- 2014-07-24 RU RU2016104221A patent/RU2671404C2/ru active
- 2014-07-24 MX MX2016000797A patent/MX362315B/es active IP Right Grant
-
2017
- 2017-09-20 CY CY20171100984T patent/CY1119482T1/el unknown
-
2019
- 2019-12-06 US US16/705,277 patent/US20200255412A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018021046A5 (enExample) | ||
| JP2009506117A5 (enExample) | ||
| CN111902417A (zh) | 一种二芳基巨环化合物、药物组合物以及其用途 | |
| JP2019524822A5 (enExample) | ||
| JP2015514135A5 (enExample) | ||
| JP2010510202A5 (enExample) | ||
| NZ596585A (en) | Isoxazolines as inhibitors of fatty acid amide hydrolase | |
| JP2013542247A5 (enExample) | ||
| JP2014507446A5 (enExample) | ||
| HRP20170531T1 (hr) | Novi terapijski pristupi za liječenje alzheimerove bolesti i povezanih poremećaja putem modulacije angiogeneze | |
| WO2013188792A3 (en) | Neuroactive steroids, compositions, and uses thereof | |
| JP2015523407A5 (enExample) | ||
| MX354423B (es) | Formulaciones de rasagilina de liberación prolongada y usos de las mismas. | |
| JP2015155440A5 (enExample) | ||
| JP2015529234A5 (enExample) | ||
| EA201171109A1 (ru) | Новая композиция замедленного высвобождения соединений, выбранных из класса миорелаксантов центрального действия | |
| JP2016511753A5 (enExample) | ||
| EP4623993A3 (en) | Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione | |
| RU2013153140A (ru) | Новая ассоциация между 4-{3-[цис-гексагидроциклопента[c] пиррол-2 (1н )- ил] пропокси} бензамидом и ингибитором ацетилхолинэстеразы и фармацевтические композиции, которые ее содержат | |
| JP2015510916A5 (enExample) | ||
| RU2015104097A (ru) | Соединения мочевины и их применение в качестве ингибиторов ферментов | |
| RU2018103940A (ru) | Фармацевтические композиции, содержащие антагонист интегрина альфа4, для применения в лечении воспалительных состояний глаза | |
| JP2016525543A5 (enExample) | ||
| JP2016537432A5 (enExample) | ||
| JP2009040767A5 (enExample) |